Latest:
Common Questions From Patients About Adalimumab Biosimilars
Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.
© 2025 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest:
Common Questions From Patients About Adalimumab Biosimilars
Latest:
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
Latest:
Opinion: Is the Ophthalmology Market Ready to Embrace Biosimilars?
Latest:
Opinion: Purple Book Patent Listings Are Only a First Step
Latest:
Biosimilar Nonmedical Switching Must Never Undermine Patient Safety